Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14287565 | 0.96 | HRH3 (0.76) | HRH3 | |
| SCHEMBL6071180 | 0.95 | HRH3 (0.69) | HRH3 | |
| SCHEMBL5106572 | 0.95 | HRH3 (0.61) | HRH3ESR2 | |
| SCHEMBL6070778 | 0.94 | HRH3 (0.74) | HRH3 | |
| SCHEMBL5097321 | 0.93 | HRH3 (0.71) | HRH3 | |
| SCHEMBL6070755 | 0.90 | HRH3 (0.62) | HRH3ESR2 | |
| SCHEMBL6687533 | 0.89 | HRH3 (0.66) | HRH3 | |
| SCHEMBL5093837 | 0.86 | HRH3 (0.91) | HRH3 | |
| SCHEMBL6071070 | 0.85 | HRH1 (0.66) | HRH3 | |
| SCHEMBL5097592 | 0.85 | ESR2 (0.52) | HRH3ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314937-B2 | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314937-B2 | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314937-B2 | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-20040110748-A1 | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses | BEAVERS LISA SELSAM (US) | 2004-06-10 | — | — | US | disclosed |
| EP-1379493-A2 | NON-IMIDAZOLE ARYL ALKYLAMINES COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly and Company (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002076925-A2 | NON-IMIDAZOLE ARYL ALKYLAMINES COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110748-A1 | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses | HRH3, HRH4, HRH2 | HRH3 1/4885ESR2 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.